Erratum to “Prognostic and predictive importance of body mass index and type 2 diabetes in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma” [EJC Skin Cancer 3 (2025) 100284] (EJC Skin Cancer (2025) 3, (S2772611825000059), (10.1016/j.ejcskn.2025.100284))

Oliver John Kennedy; Nina Glassee; Michal Kicinski; Emanuel Bührer; Sara Valpione; Sara Gandini; Stefan Suciu; Christian U. Blank; Georgina V. Long; Victoria G. Atkinson; Stéphane Dalle; Andrew M. Haydon; Andrey Meshcheryakov; Adnan Khattak; Matteo S. Carlino; Shahneen Sandhu; James Larkin; Susana Puig; Paolo A. Ascierto; Piotr Rutkowski; Dirk Schadendorf; Marye Boers-Sonderen; Anna Maria Di Giacomo; Alfonsus J.M. van den Eertwegh; Jean Jacques Grob; Ralf Gutzmer; Rahima Jamal; Alexander C.J. van Akkooi; Caroline Robert; Alexander M.M. Eggermont; Paul Lorigan; Mario Mandala

doi:10.1016/j.ejcskn.2026.101134

Erratum to “Prognostic and predictive importance of body mass index and type 2 diabetes in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma” [EJC Skin Cancer 3 (2025) 100284] (EJC Skin Cancer (2025) 3, (S2772611825000059), (10.1016/j.ejcskn.2025.100284))

Oliver John Kennedy
, Nina Glassee
, Michal Kicinski
, Emanuel Bührer
, Sara Valpione
, Sara Gandini
, Stefan Suciu
, Christian U. Blank
, Georgina V. Long
, Victoria G. Atkinson
, Stéphane Dalle
, Andrew M. Haydon
, Andrey Meshcheryakov
, Adnan Khattak
, Matteo S. Carlino
, Shahneen Sandhu
, James Larkin
, Susana Puig
, Paolo A. Ascierto
, Piotr Rutkowski

Dirk Schadendorf, Marye Boers-Sonderen, Anna Maria Di Giacomo, Alfonsus J.M. van den Eertwegh, Jean Jacques Grob, Ralf Gutzmer, Rahima Jamal, Alexander C.J. van Akkooi, Caroline Robert, Alexander M.M. Eggermont, Paul Lorigan, Mario Mandala

Research related

Research output: Contribution to journal › Comment/debate

Abstract

The publisher regrets the omission of the editor is an author declaration: The authors Susana Puig, Paul Lorigan and Dirk Schadendorf are Editors of EJC Skin Cancer and were not involved in the editorial review or the decision to publish this article.

Original language	English
Article number	101134
Journal	EJC Skin Cancer
DOIs	https://doi.org/10.1016/j.ejcskn.2026.101134
Publication status	Accepted/In press - 2026

Access to Document

10.1016/j.ejcskn.2026.101134

Fingerprint

Dive into the research topics of 'Erratum to “Prognostic and predictive importance of body mass index and type 2 diabetes in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma” [EJC Skin Cancer 3 (2025) 100284] (EJC Skin Cancer (2025) 3, (S2772611825000059), (10.1016/j.ejcskn.2025.100284))'. Together they form a unique fingerprint.

Cite this

Kennedy, O. J., Glassee, N., Kicinski, M., Bührer, E., Valpione, S., Gandini, S., Suciu, S., Blank, C. U., Long, G. V., Atkinson, V. G., Dalle, S., Haydon, A. M., Meshcheryakov, A., Khattak, A., Carlino, M. S., Sandhu, S., Larkin, J., Puig, S., Ascierto, P. A., ... Mandala, M. (Accepted/In press). Erratum to “Prognostic and predictive importance of body mass index and type 2 diabetes in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma” [EJC Skin Cancer 3 (2025) 100284] (EJC Skin Cancer (2025) 3, (S2772611825000059), (10.1016/j.ejcskn.2025.100284)). EJC Skin Cancer, Article 101134. https://doi.org/10.1016/j.ejcskn.2026.101134

Kennedy, Oliver John ; Glassee, Nina ; Kicinski, Michal et al. / Erratum to “Prognostic and predictive importance of body mass index and type 2 diabetes in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma” [EJC Skin Cancer 3 (2025) 100284] (EJC Skin Cancer (2025) 3, (S2772611825000059), (10.1016/j.ejcskn.2025.100284)). In: EJC Skin Cancer. 2026.

@article{d5256799ae3747dabe9753ca1332eb64,

title = "Erratum to “Prognostic and predictive importance of body mass index and type 2 diabetes in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma” [EJC Skin Cancer 3 (2025) 100284] (EJC Skin Cancer (2025) 3, (S2772611825000059), (10.1016/j.ejcskn.2025.100284))",

abstract = "The publisher regrets the omission of the editor is an author declaration: The authors Susana Puig, Paul Lorigan and Dirk Schadendorf are Editors of EJC Skin Cancer and were not involved in the editorial review or the decision to publish this article.",

author = "Kennedy, \{Oliver John\} and Nina Glassee and Michal Kicinski and Emanuel B{\"u}hrer and Sara Valpione and Sara Gandini and Stefan Suciu and Blank, \{Christian U.\} and Long, \{Georgina V.\} and Atkinson, \{Victoria G.\} and St{\'e}phane Dalle and Haydon, \{Andrew M.\} and Andrey Meshcheryakov and Adnan Khattak and Carlino, \{Matteo S.\} and Shahneen Sandhu and James Larkin and Susana Puig and Ascierto, \{Paolo A.\} and Piotr Rutkowski and Dirk Schadendorf and Marye Boers-Sonderen and \{Di Giacomo\}, \{Anna Maria\} and \{van den Eertwegh\}, \{Alfonsus J.M.\} and Grob, \{Jean Jacques\} and Ralf Gutzmer and Rahima Jamal and \{van Akkooi\}, \{Alexander C.J.\} and Caroline Robert and Eggermont, \{Alexander M.M.\} and Paul Lorigan and Mario Mandala",

note = "Publisher Copyright: {\textcopyright} 2026 The Authors",

year = "2026",

doi = "10.1016/j.ejcskn.2026.101134",

language = "English",

journal = "EJC Skin Cancer",

issn = "2772-6118",

publisher = "Elsevier BV",

}

Kennedy, OJ, Glassee, N, Kicinski, M, Bührer, E, Valpione, S, Gandini, S, Suciu, S, Blank, CU, Long, GV, Atkinson, VG, Dalle, S, Haydon, AM, Meshcheryakov, A, Khattak, A, Carlino, MS, Sandhu, S, Larkin, J, Puig, S, Ascierto, PA, Rutkowski, P, Schadendorf, D, Boers-Sonderen, M, Di Giacomo, AM, van den Eertwegh, AJM, Grob, JJ, Gutzmer, R, Jamal, R, van Akkooi, ACJ, Robert, C, Eggermont, AMM, Lorigan, P & Mandala, M 2026, 'Erratum to “Prognostic and predictive importance of body mass index and type 2 diabetes in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma” [EJC Skin Cancer 3 (2025) 100284] (EJC Skin Cancer (2025) 3, (S2772611825000059), (10.1016/j.ejcskn.2025.100284))', EJC Skin Cancer. https://doi.org/10.1016/j.ejcskn.2026.101134

Erratum to “Prognostic and predictive importance of body mass index and type 2 diabetes in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma” [EJC Skin Cancer 3 (2025) 100284] (EJC Skin Cancer (2025) 3, (S2772611825000059), (10.1016/j.ejcskn.2025.100284)). / Kennedy, Oliver John; Glassee, Nina; Kicinski, Michal et al.
In: EJC Skin Cancer, 2026.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Erratum to “Prognostic and predictive importance of body mass index and type 2 diabetes in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma” [EJC Skin Cancer 3 (2025) 100284] (EJC Skin Cancer (2025) 3, (S2772611825000059), (10.1016/j.ejcskn.2025.100284))

AU - Kennedy, Oliver John

AU - Glassee, Nina

AU - Kicinski, Michal

AU - Bührer, Emanuel

AU - Valpione, Sara

AU - Gandini, Sara

AU - Suciu, Stefan

AU - Blank, Christian U.

AU - Long, Georgina V.

AU - Atkinson, Victoria G.

AU - Dalle, Stéphane

AU - Haydon, Andrew M.

AU - Meshcheryakov, Andrey

AU - Khattak, Adnan

AU - Carlino, Matteo S.

AU - Sandhu, Shahneen

AU - Larkin, James

AU - Puig, Susana

AU - Ascierto, Paolo A.

AU - Rutkowski, Piotr

AU - Schadendorf, Dirk

AU - Boers-Sonderen, Marye

AU - Di Giacomo, Anna Maria

AU - van den Eertwegh, Alfonsus J.M.

AU - Grob, Jean Jacques

AU - Gutzmer, Ralf

AU - Jamal, Rahima

AU - van Akkooi, Alexander C.J.

AU - Robert, Caroline

AU - Eggermont, Alexander M.M.

AU - Lorigan, Paul

AU - Mandala, Mario

PY - 2026

Y1 - 2026

N2 - The publisher regrets the omission of the editor is an author declaration: The authors Susana Puig, Paul Lorigan and Dirk Schadendorf are Editors of EJC Skin Cancer and were not involved in the editorial review or the decision to publish this article.

AB - The publisher regrets the omission of the editor is an author declaration: The authors Susana Puig, Paul Lorigan and Dirk Schadendorf are Editors of EJC Skin Cancer and were not involved in the editorial review or the decision to publish this article.

UR - https://www.scopus.com/pages/publications/105035068306

U2 - 10.1016/j.ejcskn.2026.101134

DO - 10.1016/j.ejcskn.2026.101134

M3 - Comment/debate

AN - SCOPUS:105035068306

SN - 2772-6118

JO - EJC Skin Cancer

JF - EJC Skin Cancer

M1 - 101134

ER -

Kennedy OJ, Glassee N, Kicinski M, Bührer E, Valpione S, Gandini S et al. Erratum to “Prognostic and predictive importance of body mass index and type 2 diabetes in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma” [EJC Skin Cancer 3 (2025) 100284] (EJC Skin Cancer (2025) 3, (S2772611825000059), (10.1016/j.ejcskn.2025.100284)). EJC Skin Cancer. 2026;101134. doi: 10.1016/j.ejcskn.2026.101134